BRAF and melanoma: Studies have reported upregulation of ID3 (inhibitor of differentiation 3, a helix-loop-helix TF superfamily member) in melanomas of patients treated with a BRAF inhibitor, and silencing ID3 resulted in enhanced sensitization of melanoma to vemurafenib [48].